Immunology and Biotherapies
13.6K views | +4 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Human mabs Discovery Technology

Human mabs Discovery Technology | Immunology and Biotherapies | Scoop.it
Fully human antibodies have natural advantages; target specificity while minimizing cross reactivity and immunogenicity Integrated development platform includes complementary immuno-PET, diagnostic, ADC and radioimmunotherapy.

Our lead antibody development program is HuMab-5B1 and we started two clinical trials this year with a therapeutic agent (MVT-5873) and as a new generation PET imaging product (MVT-2163). In addition, we have identified a radioimmunotherapy agent (MVT-1075) and we plan to file an Investigational New Drug Application (NDA) with the FDA later this year.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 8, 11:21 AM
MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center. In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer. 

 The HuMab-5B1 antibody has very good tumor targeting capabilities as well as being internalized by pancreatic cancer cells. These important attributes have allowed MabVax to use the HuMab-5B1 antibody as a tumor-targeting platform upon which we have created multiple products. The antibody itself is in a Phase I clinical trial as a therapeutic agent. This same antibody when combined with a radiolabel is a potentially new generation PET imaging agent and is also in a Phase I clinical trial. We are also developing more potent HuMab-5B1 based products such as a radioimmunotherapy product when the antibody is combined with a radioisotope and lastly, an antibody drug conjugate when combined with a toxin payload. While all of the mentioned products are based on the targeting capabilities of HuMab-5B1, each product has unique characteristics and potential uses for the treatment of multiple types of solid tumors.
Scooped by Gilbert C FAURE
Scoop.it!

Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway

Articles from the current issue of @J_Immunol #STEM #Immunology Costimulation Blockade in Autoimmunity and Tran... https://t.co/pC7sE4mpyJ
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Positive results from antibody treatment in human Alzheimer's trial

Positive results from antibody treatment in human Alzheimer's trial | Immunology and Biotherapies | Scoop.it
A clinical trial of the antibody Aducanumab has yielded positive results, slowing cognitive decline in patients with early-stage Alzheimer’s disease.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Researchers devise method for bone marrow transplants without using chemotherapy

Researchers devise method for bone marrow transplants without using chemotherapy | Immunology and Biotherapies | Scoop.it
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Quantitative Comparison of Antibodies to PD-L1

Quantitative Comparison of Antibodies to PD-L1 | Immunology and Biotherapies | Scoop.it
Research from JAMA Oncology — A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

Abstract

Importance Assessment of PD-L1 (programmed cell death 1 ligand 1) expression by immunohistochemical analysis has been used as a predictive diagnostic test to identify responders and guide treatment in trials of the PD-1 (programmed cell death 1) axis inhibitors. The definition of PD-L1 positive lacks standardization, and prediction of response by immunohistochemical analysis is additionally limited by the subjective nature of this technique. 

 Objective To examine whether PD-L1 antibody reagents are interchangeable by quantitatively comparing the expression of the PD-L1 protein. Design, Setting, and Participants In this immunohistochemistry standardization study, 30 randomly selected cases of lung cancer resected from January 1, 2008, through December 31, 2009, were obtained from Yale Pathology Archives with a range of expression of PD-L1. To test for protein measurement, rather than clinical utility, a PD-L1 index tissue microarray, including cell line and tissue controls, was used. The results were then validated on a commercially available, genetically defined PD-L1 engineered cell line array with a range of controlled protein-expressing cell lines using 6 monoclonal antibodies (SP142, E1L3N, 9A11, SP263, 22c3, and 28-8). Protein levels were measured by quantitative immunofluorescence and quantitative chromogenic assessment. Data analysis was performed from September 2015 through May 2016. 

 Results Concordance between 4 antibodies revealed regression for tumor tissue cores (R2 = 0.42-0.91) and cell line cores (R2 = 0.83-0.97) by quantitative immunofluorescence in the PD-L1 index tissue microarray. All 6 antibodies had high levels of concordance (R2 = 0.76-0.99) when using chromogenic staining in isogenic cell lines. 

Conclusions and Relevance Because the antibodies are highly concordant, these results suggest that assays based on the use of these antibodies could yield concordant results. They further suggest that previously described differences in PD-L1 expression in tissue are independent of the antibody used and likely attributable to tumor heterogeneity, assay- or platform-specific variables, or other factors.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 24, 1:53 AM
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 ONLINE FIRST 

Patricia Gaule, PhD1; James W. Smithy, BS1; Maria Toki, MD1; Jamaal Rehman, MD1; Farah Patell-Socha, PhD2; Delphine Cougot, PhD2; Philippe Collin, PhD2; Paul Morrill, PhD2; Veronique Neumeister, MD1; David L. Rimm, MD, PhD1 
[+] Author Affiliations 

JAMA Oncol. Published online August 18, 2016. doi:10.1001/jamaoncol.2016.3015
Scooped by Gilbert C FAURE
Scoop.it!

Engineered T cells: the promise and challenges of cancer immunotherapy

Nature Reviews Cancer | doi:10.1038/nrc.2016.97
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Re-educating the immune system - Information Centre - Research & Innovation - European Commission

Re-educating the immune system - Information Centre - Research & Innovation - European Commission | Immunology and Biotherapies | Scoop.it
European Commission news headlines on the broader subject of research and scientific activities.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Fc receptor inside-out signaling and possible impact on antibody therapy. - PubMed - NCBI

Fc receptor inside-out signaling and possible impact on antibody therapy. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Immunol Rev. 2015 Nov;268(1):74-87. doi: 10.1111/imr.12332. Review
more...
No comment yet.
Rescooped by Gilbert C FAURE from Biotech Pharma Innovation in Immuno-Oncology & beyond. Cancer - Immunology - Immunotherapy.
Scoop.it!

Expediting Examination at the USPTO - New Pilot Program for Cancer Immunotherapy Inventions | Lexology

Expediting Examination at the USPTO - New Pilot Program for Cancer Immunotherapy Inventions | Lexology | Immunology and Biotherapies | Scoop.it
On June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented a pilot program for expediting examination of patent applications relating to cancer immunotherapy. This pilot program was designed in support of the White House’s National Cancer Moonshot initiative to accelerate immunotherapy cancer research over the next five years.

Also coined as “Patents 4 Patients”, the objective of the pilot program is to advance a US patent application directed to cancer immunotherapy out of turn for examination, if the applicant files a Petition to Make Special under the Pilot Program. Once accepted into the program, the goal is to complete examination of the application within 12 months of special status being granted.

Eligibility Requirements

The USPTO announcement highlights that the eligibility of a patent application should be in the field of oncology and must have “at least one claim encompassing a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancer cells”. The USPTO goes on to provide the following examples as acceptable claims:

administration of cells, antibodies, proteins or nucleic acids that invoke an active (or achieve a passive) immune response to destroy cancer cells;
co-administration of biological adjuvants (e.g., interleukins, cytokines, Bacillus Comette-Guerin, monophosphoryl lipid A, etc.) in combination with conventional therapies of treating cancer such as chemotherapy, radiation or surgery;
administering any vaccine that works by activating the immune system to prevent or destroy cancer cell growth; and
in vivo, ex vivo and adoptive immunotherapies, including those using autologous and/or heterologous cells or immortalized cell lines.

Via Dominique Blanchard
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Episode 14: Cell Therapy Pioneers

Episode 14: Cell Therapy Pioneers | Immunology and Biotherapies | Scoop.it
Dr Jensen and Dr Sadelain talk about how to make CAR T cell therapy more safe and effective and work in solid tumors
Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

The Power of Biologics

The Power of Biologics | Immunology and Biotherapies | Scoop.it
Learn how @Amgen has revolutionized treatment for #patients with grievous illnesses using the power of #biologics: https://t.co/unptDOuNly

A biologic is a large molecule which is made in living cells by adding a piece of DNA to a cell. The cell then either copies or translates the DNA piece into a protein which becomes the biologic medicine. Biologic medicines include therapeutic proteins and monoclonal antibodies (mAbs). They are often 200 to 1,000 times the size of a small molecule or chemical drug and are far more complex structurally. Due to both their large size and sensitivity, biologic medicines are almost always injected into the patient’s body.

Via Krishan Maggon
more...
No comment yet.
Scooped by Marcelo de Carvalho Bittencourt
Scoop.it!

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus : Nature Medicine : Nature Research

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus : Nature Medicine : Nature Research | Immunology and Biotherapies | Scoop.it
Low-dose IL-2 treatment alters the abundance of regulatory T cells, IL-17-producing T cells and follicular helper T cells, but not of T helper type 1 and 2 cells, in patients with SLE.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Viability of Human Composite Tissue Model for Experimental Study of Burns - Miao Qu - Discovery Medicine

Viability of Human Composite Tissue Model for Experimental Study of Burns - Miao Qu - Discovery Medicine | Immunology and Biotherapies | Scoop.it
Experimental studies of burns are primarily performed with animal models that have important anatomical and physiological differences relative to human systems.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Kyoto University team produces quality stem cells from umbilical blood | The Japan Times

Kyoto University team produces quality stem cells from umbilical blood | The Japan Times | Immunology and Biotherapies | Scoop.it
A research institute produces stem cells for stockpiled use in regenerative medicine from the umbilical blood of a newborn.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. - PubMed - NCBI

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Lancet Infect Dis. 2016 Apr;16(4):e47-63. doi: 10.1016/S1473-3099(16)00078-5. Research Support, Non-U.S. Gov't; Review
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis | Immunology and Biotherapies | Scoop.it
Official Full-Text Publication: CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis on ResearchGate, the professional network for scientists.
Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Human Papillomavirus (HPV) Vaccines

Human Papillomavirus (HPV) Vaccines | Immunology and Biotherapies | Scoop.it
A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer.
Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity - Cervenak - 2015 - Immunological Reviews - Wiley Online L...

Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity - Cervenak - 2015 - Immunological Reviews - Wiley Online L... | Immunology and Biotherapies | Scoop.it
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunotherapy: PD-1 says goodbye, TIM-3 says hello. - PubMed - NCBI

Immunotherapy: PD-1 says goodbye, TIM-3 says hello. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Nat Rev Clin Oncol. 2016 Apr;13(4):202-3. doi: 10.1038/nrclinonc.2016.40. Epub 2016 Mar 15. Comment
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. - PubMed - NCBI

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Oncologist. 2016 Aug 17. pii: theoncologist.2016-0164. [Epub ahead of print] REVIEW

Abstract : Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents. 

IMPLICATIONS FOR PRACTICE: The potential adverse events of immune checkpoint inhibitors differ from conventional chemotherapy and can require a multi-disciplinary approach. Continued education is important for all physicians to ensure optimal care for patients. ©AlphaMed Press. 

KEYWORDS: Immune-related adverse events; Immunotherapy; Lung cancer; Programmed cell death protein-1; Programmed death ligand-1; Toxicities

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 20, 3:30 AM
Oncologist. 2016 Aug 17. pii: theoncologist.2016-0164. [Epub ahead of print] 
PMID: 27534573 DOI: 10.1634/theoncologist.2016-0164
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. 

O'Kane GM1, Labbé C1, Doherty MK1, Young K1, Albaba H1, Leighl NB2.
Scooped by Gilbert C FAURE
Scoop.it!

NATURE REVIEWS RHEUMATOLOGY | Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?

Michiel van der Vlist, Jurgen Kuball, Timothy R. D. Radstake & Linde Meyaard AffiliationsContributionsCorresponding author Nature Reviews Rheumatology (2016)
Gilbert C FAURE's insight:
The recent success of immune checkpoint blockade in cancer therapy illustrates the importance of the inhibitory receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in the regulation of antitumour immune responses. However, blocking signalling by these inhibitory immune checkpoint receptors is also associated with substantial inflammatory effects that can resemble autoimmune responses, which is consistent with the role of these receptors in protecting the host from excessive inflammation. The human genome encodes over 300 inhibitory receptors, which represent as many opportunities to modulate inflammation in a disease-specific and tissue-specific manner. We argue that rheumatologists and oncologists should join forces to study these inhibitory immune molecules. An improved understanding of these immune checkpoints will enable both fields to make progress in exploiting inhibitory immune receptors therapeutically. In this Review, we discuss data from studies reporting the adverse inflammatory effects of cancer therapies that target immune checkpoints. We discuss the potential implications of these findings on the biological understanding of autoimmune rheumatic diseases and highlight therapeutic strategies that could be used to target inhibitory receptors for the treatment of these conditions.
more...
Krishan Maggon 's curator insight, August 20, 2:44 AM
NATURE REVIEWS RHEUMATOLOGY | REVIEW 

Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? 

 Michiel van der Vlist, Jurgen Kuball, Timothy R. D. Radstake & Linde Meyaard 
Nature Reviews Rheumatology (2016) doi:10.1038/nrrheum.2016.131 Published online 19 August 2016
Scooped by Gilbert C FAURE
Scoop.it!

JCI - Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

We're using a biomarker test to predict response to PD1 therapies. More via @jclinicalinvest https://t.co/y3Y6wwHAhB https://t.co/YtBBelxI0i
more...
No comment yet.
Rescooped by Gilbert C FAURE from Hematology
Scoop.it!

Researchers develop new strategy to limit side effects of stem cell transplants - Scienmag

Researchers develop new strategy to limit side effects of stem cell transplants - Scienmag | Immunology and Biotherapies | Scoop.it
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants. The rese..
more...
No comment yet.